药物管线
Powered by Molecule Pro™
| Program | Modality | Indication | Discovery | Optimization | IND-enabling | Phase I | Phase II | Partner |
|---|---|---|---|---|---|---|---|---|
 Wholly Owned | ||||||||
MRANK-001 | Small Molecule GLP-1RA | Obesity | Potential Best-in-Class | |||||
| Type 2 Diabetes | Potential Best-in-Class | |||||||
MRANK-106 | Dual-Target FIC | Pancreatic cancer, etc | ||||||
MRANK-108 | CDK7 | Pancreatic cancer, etc | ||||||
MRANK-111 | GLP1 analogue | Obesity, etc. | ||||||
MRANK-101 | P53 | Undisclosed | ||||||
MRANK-103 (formerly 002) | MYC-high | Oncology | ||||||
MRANK-023 | Undisclosed | Undisclosed | ||||||
 Co-Developed | ||||||||
2 programs | Undisclosed | Undisclosed | Public Biotech | |||||
8 programs | Undisclosed | Undisclosed | ||||||
 Design as a Service | ||||||||
EMRANK-016 | Allosteric Inhibitor | Oncology | PCC delivered | Public Biotech | ||||
EMRANK-189 | Undisclosed | Oncology | Lead delivered | Public Biotech | ||||